Angelini Pharma Worldwide Who we are Core areas From pipeline to health aids Our Partnerships Our Responsibility Media Career Opportunities Open main menu ANGELINI PHARMA Making the future caring for life ABOUT US TOP NEWS Women and children hit hardest by mental health disorders during the pandemic: Headway 2023 Mental Health Index Mental Health Week: the Initiatives of Angelini Pharma Angelini Pharma and Lumira Ventures launch the Angelini Lumira Biosciences Fund New study demonstrates the safety and tolerability of treatment with cenobamate tablets in adults with focal seizures The Summer issue of Aptitude Magazine is now online. Discover our stories. Angelini Pharma launches its new Career Site NEWS & publications News Press releases Magazine Press kit Women and children hit hardest by mental health disorders during the pandemic: Headway 2023 Mental Health Index The COVID 19 pandemic has exacerbated gender-related challenges with its mental health consequences disproportionately affecting women, both at work and at home. Women and children hit hardest by mental health disorders during the pandemic: Headway 2023 Mental Health Index Psychiatry Innovation Summit As the demands on mental health services grow, so will the availability of digital technologies. But how many of these technologies have been appropriately researched and validated by trained psychiatrists? Psychiatry Innovation Summit Angelini Pharma and Lumira Ventures launch the Angelini Lumira Biosciences Fund The fund has been established to invest in early-stage companies in Canada and U.S. markets, that are developing pharmaceutical therapies for central nervous system disorders (CNS) and rare diseases. Angelini Pharma and Lumira Ventures launch the Angelini Lumira Biosciences Fund SOCIAL wall Un’azienda innovativa dà valore alle sensibilità differenti delle #persone. Le fa sentire libere di esprimersi e permette loro di contribuire al meglio alla crescita dell’impresa. Ne è convinta Lorella Ragni, nostra R&D Product Lifecycle Management Executive Director. #OrangetheWorld In Italia circa 600.000 persone soffrono di #epilessia; tra queste, 125.00 sono colpite da forme resistenti alla terapia farmacologica. Per sostenerle è necessario un impegno politico, al fine di potenziare la #ricerca, effettuare diagnosi tempestive, sensibilizzare la #società e inserire questa patologia tra le malattie tempo dipendenti. Questi i temi fondamentali dell’incontro cui abbiamo preso parte: “Epilessia: le sfide di oggi”, organizzato da #CameraeSanitatis per favorire il dialogo tra istituzioni e società scientifiche. È online il quaderno dell’evento con il resoconto dettagliato di tutti gli argomenti affrontati. Leggi di più 👉 bit.ly/Epilessiaquaderno #POPSCITALIA #QSANIT Popular Science Italia Quotidiano Sanità Valorizzare le caratteristiche di ciascuno, fare della diversità una ricchezza e uno strumento indispensabile per l’innovazione: è questo il nostro obiettivo, come sostiene il nostro Global Procurement Executive Director, Davide Del Vecchio. #OrangetheWorld MEDIA center All media PUBLISHED: 24 JUN 2021 Video Making the future, caring for life Making the future, caring for life PUBLISHED: 18 MAR 2021 Video Stay Aware! Stay Aware! PUBLISHED: 8 FEB 2021 Video Epilepsy: the obstacles to be overcome in order to get out of hiding Epilepsy: the obstacles to be overcome in order to get out of hiding Next CORE areas Mental Health The burden of mental health conditions is on the rise globally and major depression, bipolar mood disorder and schizophrenia are among the 10 leading causes of disability worldwide. Mental Health Central Nervous System One of the most common brain conditions is epilepsy, which affects over 70 million people worldwide. Epilepsy has numerous neurobiological, cognitive, and psychosocial consequences. In many parts of the world, the disease is stigmatised. Central Nervous System Rare Diseases A disease is defined as rare when its prevalence, that is the number of cases present at a given time in a given population, does not exceed a certain threshold. In the European Union this threshold is set at 0.05% of the population. Rare Diseases Next DISCOVER THE SELECTION OF ARTICLES FROM THE LANCET The Lancet FOCUS ON Focus On SCIENTIFIC UPDATES Scientific Updates FROM PIPELINE to health aids Pipeline The R&D mission is built on the dynamic pipelini concept, where each project can be partially or fully developed in-house or through collaborative partnership Pipeline Investigator Initiated Trials We believe in the value of supporting scientifically and clinically study Investigator Initiated Trials. Investigator Initiated Trials Sites All sites use the most advanced technologies, with automatic control and supervision systems. Analysis and quality control, right from the raw material stage, are particularly stringent. Sites RESEARCH & ACADEMIC CENTERS AND SCIENTIFIC INSTITUTIONS DISCOVER MORE RESEARCH & ACADEMIC CENTERS AND SCIENTIFIC INSTITUTIONS Research & Academic Centers and Scientific Institutions PARTNERING DISCOVER MORE PARTNERING Partnering OUR responsability Sustainability DISCOVER MORE SUSTAINABILITY Sustainability Ethics DISCOVER MORE ETHICS Ethics Quality policy DISCOVER MORE QUALITY POLICY Quality policy ANGELINI PHARMA Worldwide AUSTRIA Employees: 47 Turnover: 25 M€ Main Therapeutic Areas: mental health, pain and inflammation, infectious diseases, cold and flu, gynaecology, oncology. Main Brands: Acutil, Akynzeo, Aloxi, Boxagrippal, Feminella, Fluimucil, Heumann, Libretto, Tantum Rosa, Tantum Verde, ThermaCare, Trittico, Unidrox, Xydalba. Website: https://www.angelini.at/ BULGARIA Employees: 68 Turnover: 16 M€ Main Therapeutic Areas: mental health, pain and inflammation, oncology, cold and flu, dermatology, oral care and sore throat, orthopaedics, rheumatology. Main Brands: Acutil, Aloxi, Aulin, Eclusa, Erdomed, Feminella, Harvoni, Iclusig, Macmiror, Monural, Piascledine, Polinail, Rosalgin, Tantum Flu, Tantum Natura, Tantum Verde, Trittico, Vellofent, Vosevi. Website: www.angelini.bg CZECH REPUBLIC Employees: 91 Turnover: 30 M€ Main Therapeutic Areas: mental health, pain, cough and cold, oncology. Main Brands: Acutil, Akynzeo, Aulin, Erdomed, Iclusig, Levopront, Libretto, Piascledine, Rosalgin, Tantum Verde, Trittico, Vellofent. Website: www.angelini.cz GERMANY Employees: 58 Turnover: 38 M€ Main Therapeutic Areas: topical pain relief, colds and nutritional supplements. Main Brands: Acutil, BoxaGrippal, Heumann, Tantum Verde, ThemaCare. Website: https://www.angelinipharma.de/ GREECE Employees: 36 Turnover: 24 M€ Main Therapeutic Areas: mental health, pain and inflammation, infectious diseases, fertility, gastroenterology, oral care and sore throat. Main Brands: Asacol, Budecol, Prixina, Propol Verde, Tantogrip, Tantum Verde, Trittico, Vellofent, Xydalba. Website: www.angelini.gr HUNGARY Employees: 22 Turnover: 8 M€ Main Therapeutic Areas: mental health, pain and inflammation, oncology, cold and flu, gynaecology, haematology, onycomycosis. Main Brands: Aloxi, Akynzeo, Erdomed, Feminella, Hyalgan, Iclusig, Kitonail, Macmiror Complex, Mesulid, Tantum Rosa, Tantum Verde, Trittico. ITALY Employees: 1559 Turnover: 556 M€ Main Therapeutic Areas: rare diseases, mental health, pain and inflammation, infectious diseases, cold and flu, disinfection, oral care and sore throat, personal care, food supplements. Main Brands: Acutil, Adasuve, Alghedon, Amuchina, Amukine Med, Aulin, Broncho Vaxom, Colpogyn, Daparox, Dubine, Energya, Esto, GelEnterum, Ginetantum, Infasil, Latuda, Moment, Portolac, Resilient, Tachicaf, Tachidol, Tachifene, Tachifludec, Tachipirina, Tantum Rosa, Tantum Verde, ThermaCare, Trittico, Vellofent, Xydalba. Website: www.angelinipharma.it POLAND Employees: 238 Turnover: 53 M€ Main Therapeutic Areas: mental health, pain and inflammation, infectious diseases, oncology, cold and flu, gynaecology, rheumatology, respiratory. Main Brands: Akynzeo, Erdomed, Erdomed Muko, Glimbax, Ketospray, Latuda, Levopront, Macmiror Complex, Magvit, Macmiror, Piascledine, Ruskorex, Tantum Flu, Tantum Rosa, Tantum Verde, Trittico, Vellofent, Visolvit, Xydalba. Website: www.angelinipharma.pl PORTUGAL Employees: 109 Turnover: 44 M€ Main Therapeutic Areas: mental health, pain and inflammation, cold and flu, dermocosmetic. Main Brands: Acutil, Adalgur, Barral, Lepicortinolo, Magnesium OK, Optimus, Tantum Verde, ThermaCare, Triticum, Vellofent. Website: www.angelinipharma.pt ROMANIA Employees: 87 Turnover: 33 M€ Main Therapeutic Areas: mental health, pain and inflammation, oncology, respiratory system. Main Brands: Acutil, Akynzeo, Aloxi, Aulin, Erdomed, Feminella, Fluimucil, Iclusig, Kitonail, Macmiror Complex, Monural, Piascledine, Tantum Rosa, Tantum Verde, Trittico, Xydalba. Website: www.angelini.ro RUSSIA Employees: 121 Turnover: 24 M€ Main Therapeutic Areas: mental health, oral care and sore throat, gynaecology, reproductive health. Main Brands: Alterpur, Lactanza, Latuda, Meriofert, Tantum Propolis, Tantum Rosa, Tantum Verde. Website: www.angelini.ru SLOVAK REPUBLIC Employees: 44 Turnover: 13 M€ Main Therapeutic Areas: mental health, pain and inflammation, oncology, oral care and sore throat, respiratory system. Main Brands: Akynzeo, Erdomed, Piascledine, Tantum Verde, Trittico. SPAIN Employees: 200 Turnover: 84 M€ Main Therapeutic Areas: mental health, palliative and pain, oncology, infectious diseases, ophthalmology, rheumatology, fertility, consumer healthcare. Main Brands: Amuchina, Avaric, Benferol, Condrosulf, Deprax, Estila, Fostipur, Juanola, Iodim, Latuda, Leotron, Lubristil, Meriofert, Soñodina, Tantum Verde, Thermacare, Xydalba. Website: www.angelinipharma.es TURKEY Employees: 145 Turnover: 11 M€ Main Therapeutic Areas: mental health, musculoskeletal system, respiratory system. Main Brands: Anzyl, Batiodin, Desyrel, Farhex, Gastor, Perebron, Samigra, Tantum Tablet, Tantum Gel, Tantum Verde, Vellajen. Website: www.angelini.com.tr USA Employees: 127 Turnover: 19 M€ Main Therapeutic Areas: disinfectant, infection control, pain relief, catheter care. Main Brands: Alcavis 50, Alcavis Bleach-Wipe, Aniosgel, ExSept Plus, Peracidin, Thermacare. Website: www.angelini-us.com Terms of use Privacy Transparency Cookie Policy Contact Site map Credits Angelini S.p.a. - Viale Amelia 70, 00181 Roma - P.IVA 01258691003 e C.F. Numero di iscrizione registro imprese: 03907010585 - Ufficio del registro delle imprese: Roma - Capitale: € 165.000.000 I.V. Copyright 2021 © Angelini S.p.a. - All Rights Reserved